| Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases. | |
| | |
MedLine Citation:
|
PMID: 23054327 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Acromegaly is a rare, chronic, and debilitating disease that results from excessive growth hormone production. Clinically, this disease is associated with enlargement of soft tissue, excessive skeletal growth, and increased risk of cardiovascular disease. Acromegaly is often diagnosed late, when a wide range of comorbidities may already be present. First-line therapy for acromegaly is typically surgery; but a number of highly-specific pharmacological agents have recently enabled a more aggressive medical management of acromegaly. Since surgical cure of acromegaly is low for macroadenomas, medical control of active acromegaly is an important component of treatment. There are no published US data currently available regarding real-world rates of comorbidities and treatment patterns among patients with acromegaly. This retrospective study examined the comorbidities and treatment patterns of 949 health plan enrollees, who had acromegaly diagnosis and/or procedure codes in an administrative claims database from July 1, 2002 through June 30, 2010. Acromegaly was associated with high rates of hypertension and diabetes along with a number of other comorbidities. The incidence of comorbidities was highest among patients with acromegaly-related treatment, which may have resulted, in part, from inadequate disease management and/or poor disease control. Unexpectedly, 55 % of patients identified with acromegaly received no treatment for acromegaly (i.e., surgery, radiotherapy, and medication) and only 28 % received a medication treatment during the observation period. However, some patients may have received a curative surgery prior to the observation period, which may have reduced the use of other acromegaly-related treatments during the study period. Of those treated with medications, the most common first medications were octreotide, cabergoline, and bromocriptine. Given the high incidence of serious comorbidities associated with active acromegaly, earlier diagnosis and treatment, along with appropriate follow-up care, may potentially avoid the life-long consequences of uncontrolled disease. |
| | |
Authors:
|
Tanya Burton; Elisabeth Le Nestour; Tim Bancroft; Maureen Neary |
Related Documents
:
|
23508857 - Treating equine paraphimosis. 23321497 - Long term re-evaluation of primary aldosteronism after medical treatment reveals high p... 23631097 - Managing hay fever during the exam period. 23135647 - Safety of dermal fillers. 1098447 - Osteogenesis imperfecta. review of the literature with presentation of 29 cases. 9578937 - Three who made an association: i. sir william osler, 1849-1919. ii. george milbry gould... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-10-11 |
Journal Detail:
|
Title: Pituitary Volume: - ISSN: 1573-7403 ISO Abbreviation: Pituitary Publication Date: 2012 Oct |
Date Detail:
|
Created Date: 2012-10-11 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9814578 Medline TA: Pituitary Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Health Economics and Outcomes Research, OptumInsight, Waltham, MA, 02493, USA, tanya.burton@optum.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: An unusual cause of non-infectious peritonitis in a peritoneal dialysis patient.
Next Document: Aspergillus fumigatus and Other Thermophilic Fungi in Nests of Wetland Birds.